Pharmafile Logo

News and Press Releases

Codexis signs agreement to manufacture 50g siRNA using its ECO Synthesis Manufacturing Platform

4 March 2026 -- California, US -- Codexis, Inc, a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with...

Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2026

Codexis
200 Penobscot Drive
 Redwood City, California 94063
 650-421-8100

BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure

Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds Aurase shows dual action on chronic wound debridement and healing SolasCure preparing fund raising for...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 25, 2026

BRAINBiotech
public@brain-biotech.com
Darmstädter Straße 34 – 36 64673 Zwingenberg Deutschland

SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel

Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of development Data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 24, 2026

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...

Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025

Elixir Medical
info@elixirmedical.com
920 N. McCarthy Blvd. Milpitas, CA 95035 U.S.

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25

Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...

Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025

Cleerly
info@cleerlyhealth.com
1099 18th St #2860, Denver, CO 80202

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

Novonesis probiotic strain receives health claim in Canada

Health Canada authorizes functional claims that the new probiotic strain CLEPIUS™ “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adults” 11 March 2024 -- Copenhagen,...

Category: Biotechnology, Other, Pharmaceutical
Posted: March 11, 2025

Novonesis
Biologiens Vej 2 2800 Lyngby Denmark

Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia

Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations 10 February 2025 -- Panchkula, India -- Venus Remedies Limited, a leading Indian exporter...

Category: Drug Delivery, Other, Pharmaceutical
Posted: February 10, 2025

Venus Remedies
info@venusremedies.com, bd@venusremedies.com
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113

Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference

26 March 2024 -- California, US -- Shockwave Medical, a pioneer in the development and commercialisation of transformational technologies for the treatment of cardiovascular disease, announced today that the company...

Category: Biotechnology
Posted: March 26, 2024

Shockwave Medical
media@shockwavemedical.com
5403 Betsy Ross Drive Santa Clara, CA, 95054 - USA

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthenpipeline in cardiovascular disease

25 March, 2024 -- Bagsværd, Denmark, and Hannover, Germany -- Novo Nordisk and CardiorPharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to€1.025bn, including an upfront...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 26, 2024

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark